|
Integrated Efficacy and Safety of Glecaprevir/Pibrentasvir
in Patients With Psychiatric Disorders
|
|
|
Reported by Jules Levin
Internati onal Network on Hepatitis Care in Substance Users, 7th International Symposium, 19-21 September 2018, Lisbon, Portugal  
David Back1, Pamela Belperio2, Mark Bondin3, Francesco Negro4, Andrew H Talal5, Caroline Park3,
Yang Lei3, Brett Pinksy3, Eric Crown3, Federico Mensa3, Fiona Marra1
1University of Liverpool, Liverpool, United Kingdom; 2US Department of Veterans Aff airs, VA Palo Alto Healthcare System, Palo Alto, California, United States; 3AbbVie Inc., North Chicago, Illinois, United States; 4University of Geneva, Geneva, Switzerland; 5Jacobs School of Medicine and Biomedical Sciences, University of Buff alo, Buff alo, New York, United States
![0925181](../images%20/092518/092518-3/0925181.gif)
![0925182](../images%20/092518/092518-3/0925182.gif)
![0925183](../images%20/092518/092518-3/0925183.gif)
![0925184](../images%20/092518/092518-3/0925184.gif)
![0925185](../images%20/092518/092518-3/0925185.gif)
![0925186](../images%20/092518/092518-3/0925186.gif)
![0925187](../images%20/092518/092518-3/0925187.gif)
![0925188](../images%20/092518/092518-3/0925188.gif)
![0925189](../images%20/092518/092518-3/0925189.gif)
![09251810](../images%20/092518/092518-3/09251810.gif)
![09251811](../images%20/092518/092518-3/09251811.gif)
![09251812](../images%20/092518/092518-3/09251812.gif)
![09251813](../images%20/092518/092518-3/09251813.gif)
| |
|
|
|
|
|